Ngā hua rapu - J. Dalmau
- E whakaatu ana i te 1 - 2 hua o te 2
-
1
Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment—the QUALIPROST study mā Antonio Alcaraz, Joaquı́n Carballido, Miguel Unda, R.A. Medina López, J.L. Ruiz-Cerdá, F Rodríguez-Rubio, D. García-Rojo, Francisco Brenes-Bermúdez, J.M. Cózar-Olmo, V. Baena-González, J. Dalmau
I whakaputaina 2016Artigo -
2
Efficacy and safety of a hexanic extract of <i>Serenoa repens</i> (Permixon<sup>®</sup>) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperpla... mā R. Vela‐Navarrete, Antonio Alcaraz, A. Rodrı́guez-Antolı́n, B. Miñana, J.M. Fernández Gómez, J.C. Angulo, David Castro‐Díaz, Javier Otero, Francisco Brenes, Joaquı́n Carballido, José Molero, Antonio Fernández‐Pro Ledesma, José Manuel Cózar Olmos, J. Dalmau, Isaac Subirana Cachinero, Michael Herdman, Vincenzo Ficarra
I whakaputaina 2018Revisão
Ngā utauta rapu:
Ngā marau whai pānga
Cancer
Internal medicine
International Prostate Symptom Score
Lower urinary tract symptoms
Medicine
Prostate
Urology
5 Alpha-Reductase Inhibitor
Adverse effect
Benign prostatic hyperplasia (BPH)
Cochrane Library
Confidence interval
Finasteride
Hyperplasia
Meta-analysis
Nephrology
Nocturia
Nursing
Observational study
Outpatient clinic
Prospective cohort study
Prostate cancer
Quality of life (healthcare)
Randomized controlled trial
Sexual function
Urinary system
Watchful waiting